Alexa Fluor 647 anti-human CD272 BTLA Antibody anti-CD272 - MIH26,BioLegend,344519
Additional reported applications (for the relevant formats) include: inhibition of T cell proliferation and cytokine production1. Clone MIH26 has agonistic activity on BTLA, resulting in the inhibition of activation.The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for use inin vitroandin vivobiofunctional assays.
Host
Mouse
Reactivity
Human
Application
FC -Quality tested
Platform ID
BAB504614664

BioLegend
Contact
Tel: 1-858-455-9588
Fax: +49 (4131) 7023913
Email:
Specifications
Scientific Background
B and T lymphocyte attenuator (BTLA) is an Ig superfamily coinhibitory receptor with structural similarity to programmed cell death 1 (PD-1) and CTLA-4. BTLA is expressed on B cells, T cells, macrophages, dendritic cells, NKT cells, and NK cells. Engagement of BTLA by its ligand Herpes Virus Entry Mediator (HVEM) is critical for negatively regulating immune response. The absence of BTLA with HVEM inhibitory interactions leads to increased experimental autoimmune encephalomyelitis severity, enhanced rejection of partially mismatched allografts, an increased CD8+memory T cell population, increased severity of colitis, and reduced effectiveness of T regulatory cells. BTLA plays an important role in the induction of peripheral tolerance of both CD4+and CD8+T cells in vivo. Tolerant T cells have significant up-regulated expression of BTLA compared with effector and naïve T cells. BTLA may cooperate with CTLA-4 and PD-1 to control T cell tolerance and autoimmunity. It has been reported that BTLA may regulate T cell function through binding to B7-H4.
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
Please provide the required information below so that we can quickly source your products.
